论文部分内容阅读
目的:对老年冠心病心律失常患者采用参松养心胶囊联合美托洛尔缓释片治疗的临床价值进行探讨分析。方法:收集本院88例老年冠心病心律失常患者作为观察对象,根据患者入院尾号的奇偶数将其分为观察组(45例)与对照组(43例),对照组仅应用美托洛尔缓释片,观察组在对照组治疗基础上联合应用参松养心胶囊。结果:观察组缺血次数明显少于对照组,缺血持续时间明显短于对照组,且脑钠肽(BNP)水平明显低于对照组(P<0.05);观察组总治疗有效率显著高于对照组(P<0.05);两组不良反应率对比,差异无统计学意义(P>0.05)。结论:应用参松养心胶囊联合美托洛尔缓释片治疗老年冠心病心律失常患者,能够显著减少心律失常发生次数,改善患者心肌缺血症状,提高安全性。
Objective: To investigate the clinical value of Shensong Yangxin Capsule combined with metoprolol sustained-release tablets in elderly patients with coronary heart disease. Methods: A total of 88 elderly patients with coronary heart disease and arrhythmia were collected and divided into the observation group (45 cases) and the control group (43 cases) according to the odd and even numbers of the admission tail number. The control group received only metoprolol Seoul sustained release tablets, the observation group in the control group based on the combination of Shen Song Yang Xin capsule. Results: The number of ischemia in observation group was significantly less than that in control group, the duration of ischemia was significantly shorter than that in control group, and the level of BNP was significantly lower than that in control group (P <0.05). The total effective rate in observation group was significantly higher In the control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: The application of Shensong Yangxin Capsule combined with metoprolol sustained-release tablets in elderly patients with coronary heart disease can significantly reduce the incidence of arrhythmia, improve myocardial ischemia symptoms and improve safety.